Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study.

Switching dual therapy with dolutegravir (DTG) plus rilpivirine (RPV) was assessed in the SWORD-1 and SWORD-2 studies. Real-life data regarding the immunological impact of this approach on CD4+ and CD8+ T lymphocyte counts and the CD4/CD8 ratio are scarce. We evaluated this strategy on the basis of...

Descripción completa

Detalles Bibliográficos
Autores: Troya, Jesus, Duenas, Carlos, Irazola, Idoia, de Los Santos, Ignacio, de la Fuente, Sara, Gil, Desire, Hernandez, Cristina, Galindo, Maria Jose, Gomez, Julia, Delgado, Elisabeth, Moreno-Garcia, Estela, Posada, Guillermo, Aldamiz, Teresa, Iribarren, Jose Antonio, Guerra, Jose Manuel, Moran, Miguel Angel, Galera, Carlos, Fuente, Javier, Pelaez, Ana, Cervero, Miguel, Garcinuno, Maria, Montero, Marta, Ceballos, Francisco, Buzon, Luis
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:INCLIVA
Repositorio:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
OAI Identifier:oai:incliva.fundanetsuite.com:p16751
Acceso en línea:https://incliva.portalinvestigacion.com/publicaciones/16751
Access Level:acceso abierto
id ES_a2f4fe8fbd64e3a2011cc89618a50876
oai_identifier_str oai:incliva.fundanetsuite.com:p16751
network_acronym_str ES
network_name_str España
repository_id_str
spelling Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study.Troya, JesusDuenas, CarlosIrazola, Idoiade Los Santos, Ignaciode la Fuente, SaraGil, DesireHernandez, CristinaGalindo, Maria JoseGomez, JuliaDelgado, ElisabethMoreno-Garcia, EstelaPosada, GuillermoAldamiz, TeresaIribarren, Jose AntonioGuerra, Jose ManuelMoran, Miguel AngelGalera, CarlosFuente, JavierPelaez, AnaCervero, MiguelGarcinuno, MariaMontero, MartaCeballos, FranciscoBuzon, LuisSwitching dual therapy with dolutegravir (DTG) plus rilpivirine (RPV) was assessed in the SWORD-1 and SWORD-2 studies. Real-life data regarding the immunological impact of this approach on CD4+ and CD8+ T lymphocyte counts and the CD4/CD8 ratio are scarce. We evaluated this strategy on the basis of clinical practice data.A multicentric retrospective cohort study.Treatment-experienced virologically suppressed HIV-1-infected patients who were switched to DTG plus RPV were included. Using different models for paired data, we evaluated the efficacy and immune status in terms of CD4+ and CD8+ T-cell counts and CD4/CD8 ratio at 24 and 48 weeks of treatment.The study population comprised of 524 patients from 34 centers in Spain. Men accounted for 76.9% of patients, with a median age of 53 years. Patients receiving DTG plus RPV reached weeks 24 and 48 in 99.4% and 83.8% of cases, respectively, with only three (0.57%) virological failures. We found a significant decrease in CD8+ T-cell count (log OR -40) at week 24 and an increase in CD4+ T-cell count at week 48 (log OR +22.8). In acquired immunodeficiency syndrome-diagnosed patients, we found a significant increase in the CD4+ T-cell count at week 48 (log OR = 41.7, P = .0038), but no significant changes in the CD8+ T-cell count (log OR = -23.4, P = .54). No differences were found in the CD4/CD8 ratio between the acquired immunodeficiency syndrome subgroup and sex or age.In patients with controlled treatment, dual therapy with DTG plus RPV slightly improved the immune status during the first 48 weeks after switching, not only in terms of CD4+ T-cell count but also in terms of CD8+ T-cell count, with persistently high rates of viral control.LIPPINCOTT WILLIAMS & WILKINS2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://incliva.portalinvestigacion.com/publicaciones/16751MEDICINEISSN: 00257974ISSNe: 15365964reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVAinstname:INCLIVAInglésinfo:eu-repo/semantics/openAccessoai:incliva.fundanetsuite.com:p167512026-06-07T16:35:31Z
dc.title.none.fl_str_mv Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study.
title Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study.
spellingShingle Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study.
Troya, Jesus
title_short Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study.
title_full Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study.
title_fullStr Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study.
title_full_unstemmed Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study.
title_sort Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study.
dc.creator.none.fl_str_mv Troya, Jesus
Duenas, Carlos
Irazola, Idoia
de Los Santos, Ignacio
de la Fuente, Sara
Gil, Desire
Hernandez, Cristina
Galindo, Maria Jose
Gomez, Julia
Delgado, Elisabeth
Moreno-Garcia, Estela
Posada, Guillermo
Aldamiz, Teresa
Iribarren, Jose Antonio
Guerra, Jose Manuel
Moran, Miguel Angel
Galera, Carlos
Fuente, Javier
Pelaez, Ana
Cervero, Miguel
Garcinuno, Maria
Montero, Marta
Ceballos, Francisco
Buzon, Luis
author Troya, Jesus
author_facet Troya, Jesus
Duenas, Carlos
Irazola, Idoia
de Los Santos, Ignacio
de la Fuente, Sara
Gil, Desire
Hernandez, Cristina
Galindo, Maria Jose
Gomez, Julia
Delgado, Elisabeth
Moreno-Garcia, Estela
Posada, Guillermo
Aldamiz, Teresa
Iribarren, Jose Antonio
Guerra, Jose Manuel
Moran, Miguel Angel
Galera, Carlos
Fuente, Javier
Pelaez, Ana
Cervero, Miguel
Garcinuno, Maria
Montero, Marta
Ceballos, Francisco
Buzon, Luis
author_role author
author2 Duenas, Carlos
Irazola, Idoia
de Los Santos, Ignacio
de la Fuente, Sara
Gil, Desire
Hernandez, Cristina
Galindo, Maria Jose
Gomez, Julia
Delgado, Elisabeth
Moreno-Garcia, Estela
Posada, Guillermo
Aldamiz, Teresa
Iribarren, Jose Antonio
Guerra, Jose Manuel
Moran, Miguel Angel
Galera, Carlos
Fuente, Javier
Pelaez, Ana
Cervero, Miguel
Garcinuno, Maria
Montero, Marta
Ceballos, Francisco
Buzon, Luis
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
description Switching dual therapy with dolutegravir (DTG) plus rilpivirine (RPV) was assessed in the SWORD-1 and SWORD-2 studies. Real-life data regarding the immunological impact of this approach on CD4+ and CD8+ T lymphocyte counts and the CD4/CD8 ratio are scarce. We evaluated this strategy on the basis of clinical practice data.A multicentric retrospective cohort study.Treatment-experienced virologically suppressed HIV-1-infected patients who were switched to DTG plus RPV were included. Using different models for paired data, we evaluated the efficacy and immune status in terms of CD4+ and CD8+ T-cell counts and CD4/CD8 ratio at 24 and 48 weeks of treatment.The study population comprised of 524 patients from 34 centers in Spain. Men accounted for 76.9% of patients, with a median age of 53 years. Patients receiving DTG plus RPV reached weeks 24 and 48 in 99.4% and 83.8% of cases, respectively, with only three (0.57%) virological failures. We found a significant decrease in CD8+ T-cell count (log OR -40) at week 24 and an increase in CD4+ T-cell count at week 48 (log OR +22.8). In acquired immunodeficiency syndrome-diagnosed patients, we found a significant increase in the CD4+ T-cell count at week 48 (log OR = 41.7, P = .0038), but no significant changes in the CD8+ T-cell count (log OR = -23.4, P = .54). No differences were found in the CD4/CD8 ratio between the acquired immunodeficiency syndrome subgroup and sex or age.In patients with controlled treatment, dual therapy with DTG plus RPV slightly improved the immune status during the first 48 weeks after switching, not only in terms of CD4+ T-cell count but also in terms of CD8+ T-cell count, with persistently high rates of viral control.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://incliva.portalinvestigacion.com/publicaciones/16751
url https://incliva.portalinvestigacion.com/publicaciones/16751
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv LIPPINCOTT WILLIAMS & WILKINS
publisher.none.fl_str_mv LIPPINCOTT WILLIAMS & WILKINS
dc.source.none.fl_str_mv MEDICINE
ISSN: 00257974
ISSNe: 15365964
reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname:INCLIVA
instname_str INCLIVA
reponame_str r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
collection r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869415340716326912
score 15,811543

Similares en LA Referencia